A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to assess the ability to slow down or stop the growth of cancer with amivantamab combined with either lazertinib or chemotherapy (carboplatin and pemetrexed) in participants with resectable, epidermal growth factor receptor (EGFR) mutated, Stage II-IIIB non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer. NSCLC may occur due to mutations (changes) in many genes, including EGFR.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent musi mieć potwierdzonego raka płuca, który można całkowicie usunąć operacyjnie.
- •Chirurgiczne usunięcie guza musi być uznane za możliwe przez zespół lekarzy.
- •Pacjent musi wyrazić zgodę na pobranie próbki tkanki guza, jeśli jest to możliwe i potrzebne.
✗ Disqualifies
- •Choroby, które nie są pod kontrolą.
- •Problemy z płucami (zapalenie płuc lub inne choroby płuc) lub podejrzenie takich problemów.
- •Alergie lub nadwrażliwość na którykolwiek ze składników leków badanych w tym leczeniu.
- •Obecność innych mutacji genetycznych w raku płuca, oprócz tych, które są badane w tym protokole.
- •Wcześniejsze leczenie raka płuca innymi lekami przeciwnowotworowymi, w tym chemioterapią lub lekami celowanymi.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (23)
City of Hope
Duarte, United States
City of Hope 1
Irvine, United States
Providence Cancer Center
Portland, United States
Providence Oncology and Hematology Care Clinic Westside
Portland, United States
Princess Margaret Hospital
Toronto, Canada
Beijing Cancer Hospital of Peking University
Beijing, China
Sichuan Cancer Hospital
Cheng Du Shi, China
West China Hospital Sichuan University
Chengdu, China
Guangdong Provincial People's Hospital
Guangzhou, China
Shandong Cancer Hospital
Jinan, China
Shanghai Pulmonary Hospital
Shanghai, China
Tianjin Chest Hospital
Tianjin, China
Kyungpook National University Chilgok Hospital
Buk Gu, South Korea
Pusan National University Hospital
Busan, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Hosp. Gral. Univ. Dr. Balmis
Alicante, Spain
Hosp. Gral. Univ. Gregorio Maranon
Madrid, Spain
Taichung Veterans General Hospital
Taichung, Taiwan
Chi Mei Medical Center Liouying Branch
Tainan, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
NTU Biomedical Park Hospital
Zhubei, Taiwan
Trial contact
Study Contact
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.